February 12, 2019
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 11, 2019
- Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
February 5, 2019
- Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia
January 31, 2019
- Apellis Pharmaceuticals Appoints Thomas Lackner as Senior Vice President, Head of Europe
January 2, 2019
- Apellis Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
December 20, 2018
- Apellis Pharmaceuticals’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of C3 Glomerulopathy
December 20, 2018
- Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy
December 3, 2018
- Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH
December 2, 2018
- Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH
November 20, 2018
- Apellis Pharmaceuticals Expands Leadership Team, Appoints Adam Townsend as Chief Commercial Officer
Displaying 1 - 10 of 48 results
